Covid Vaccine Race

The to-be-reviewed assessment of real-world vaccine recipients suggests 51% greater efficacy with BNT162b2 after 13-24 days.

The European Medicines Agency announced today it has recommended granting a commercial marketing authorization (CMA) to the company for its vaccine.

Data for its phase 3 trial shows differing levels of protection for moderate to severe disease depending on the geographic region.

The findings accompany news that the company is working on new vaccines to address more transmissible SARS-CoV-2 variants.

The US Centers for Disease Control and Prevention shares a similar outlook with the organization.

After setbacks to its own vaccine candidate, the major drug developer has agreed to aide in production for Europe-bound doses.

Using the Defense Production Act to aid in the effort remains on the table.

Roughly half the US population is now eligible to get a COVID-19 vaccine, according to health guidelines, but supply cannot keep up with demand.

On November 5, England went into a large scale lockdown to help curb the spread of the virus. This resurgence wasn’t unique to the UK though, but many have questioned the efficacy of such lockdowns, especially second ones.

Company announced it will continue developing 2 investigational therapeutics.

The United States and China make up nearly half of the globes vaccinations.

However, there is a six-fold reduction in neutralizing titers in the B.1.351 variant from South Africa, so the company is exploring strategies aimed against new variants.

Saliva testing for coronavirus disease 2019 (COVID-19) is as effective as the standard nasopharyngeal tests, according to a new study by investigators at McGill University.

With the news that the Pfizer and BioNtech COVID-19 vaccine vials can provide an extra dose, the federal agency updated the labeling so as to enable usage of low dead-volume syringes to extract it.

In a move being ill-received by clinicians, the COVID-19 vaccine producer is lessening the count of vials being supplied to the government through July.

Project aims for additional good-paying jobs, combatting the climate crisis, advancing racial equity, and building back better than before.

If the current recommended dosing schedules for the vaccines are not “feasible,” then the agency said vaccines may be scheduled for administration up to 42 days between the first and second doses.

In organizations with 50 or fewer employees, an average of only 29% of healthcare workers had been offered the vaccine.

The US tops the list of total vaccine administrations despite a lagging rollout and ongoing issues.

Current trial evidence is severely lacking for the at-risk group, but does clinical history suggest safety?

An interview on new survey data suggesting a majority of fertility and pregnant patients are not interested in the currently available vaccines.

State and federal officials confirmed Friday that promise for a reserve supply of vaccines meant for second doses is actually unavailable.

The American College of Physicians offered recommendations on the distribution and administration of vaccines.

This vaccine is meant to be delivered as a single dose administration as compared to other vaccines that have been authorized and in development that require a booster shot.

The Department of Health and Human Services is expected to announce the new guidelines at noon.

Newly published data shows just 0.6% of patients receiving the Moderna mRNA vaccine reported serious adverse events, a rate identical to that of the placebo group.

China has overtaken the US and is currently leading all countries in total vaccine administrations.

The agency warns SARS-CoV-2 mutations can trigger potential false negative results in molecular tests.

The international organization offers guidance on various groups and if they should be consider getting the vaccine.